摘要
Abstract
OBJECTIVE: To observe the therapeutic efficacy of combined therapy of repaglinide and metformin in the treatment of newly diagnosed obese type 2 diabetes mellitus. METHODS: 156 patients in our hospital from January 2005 to February 2010 with newly diagnosed type 2 diabetes mellitus were treated with repaglinide and metformin to cross-reference treat with repaglinide independently, metformin independently for 12 weeks(each group included 52 cases). The fasting blood glucose (FBG), postprandial 2 h blood glucose (2hBG), glycosylated hemoglobin (HbA1c) and body mass index (BMI) were detected and analyzed before and after treatment. RESULTS: After treatment, FBG, 2hBG, HbAlc, BMI were as follows: ( 6.5 ± 0.58) mmol· L-1, (7.42 ± 0.61) mmol· L-1, (6.32 ± 1.98)％, (24.2 ± 0.65) kg·m-2 in treatment group. Compared with control group, they all decreased significanfiy in treatment group (P＜0.05). And the adverse reactions were mild. CONCLUSION: Repaglinide combined with metformin is an effective method for newly diagnosed type 2 obese diabetes mellitus, and has low adverse reaction.关键词
瑞格列奈/二甲双胍/肥胖型/2型糖尿病/对照Key words
Repaglinide/ Metformin/ Obese/ Type 2 diabetes mellitus/ Cross-reference分类
医药卫生
